摘要
目的研究肾细胞癌(RCC)患者中血清生长分化因子15(GDF-15)水平的变化及其临床诊断和预后意义。方法收集2018年1月至2019年12月在本院接受治疗的80例RCC患者的血清样本,同时收集同期60例健康人群及112例其他实体瘤患者的血清样本;采用酶联免疫吸附法(ELISA)测定所有患者的血清GDF-15水平,并进一步分析GDF-15水平与患者临床病理参数的相关性;采用受试者工作特征(ROC)曲线、Kaplan-Meier和Log-Rank检验评估GDF-15在RCC诊断和预后中的临床价值。结果与健康人群和其他实体瘤患者比较,RCC患者的血清GDF-15水平显著升高(P<0.05);血清GDF-15水平与性别、Fuhrman分级、临床分期和转移状态均有相关性(均P<0.05),但与年龄、肿瘤大小和免疫组化类型无相关性(均P>0.05)。ROC曲线分析发现血清GDF-15水平可以用于RCC患者和健康人群的鉴别诊断[曲线下面积(AUC)=0.835,灵敏度为0.791,特异度为0.912]以及肿瘤转移和未转移RCC患者的鉴别诊断(AUC=0.732,灵敏度为0.897,特异度为0.654);Kaplan-Meier和log-Rank检验结果显示,低GDF-15水平患者的总生存率明显高于高GDF-15水平患者(P=0.025)。结论血清GDF-15水平升高可能是一种新的肾细胞癌诊断和预后标志物。
Objective To determine the serum levels of growth differentiation factor 15(GDF-15)in patients with renal cell carcinoma(RCC)and clinical diagnosis and prognostic significance.Methods Blood samples from 80 patients with RCC in our hospital from January 2018 to December 2019 were collected,as well as serum samples from 60 healthy people and 112 other solid tumor patients during the same period.The serum GDF-15 level of all patients was determined by enzyme-linked immunosorbent assay(ELISA),and the correlation between GDF-15 level and clinicopathological parameters was further analyzed.Receiver operating characteristic(ROC)curve,Kaplan-Meier and log-Rank tests were used to evaluate the clinical value of GDF-15 in the diagnosis and prognosis of RCC.Results Serum GDF-15 levels were significantly higher in patients with RCC compared with healthy controls and patients with other types of cancers(P<0.05),and associated with sex,Fuhrman grades,clinical stage,and metastasis states(all P<0.05),but not with age,tumor size,and histological types(all P>0.05).ROC curve analysis showed that serum GDF-15 levels could be used to differentiate between RCC patients and healthy people[area under the ROC curve(AUC)=0.835,sensitivity 0.791,specificity 0.912],and patients with metastatic and non-metastatic RCC(AUC=0.732,sensitivity 0.897,specificity 0.654).Kaplan-Meier and log-Rank test results showed that the overall survival rate of patients with low GDF-15 level was significantly higher than that of patients with high GDF-15 level(P=0.025).Conclusions The elevated serum GDF-15 level may be a novel diagnostic and prognostic biomarker for patients with RCC.
作者
胡丽君
曾凡思
Hu Lijun;Zeng Fansi(Department of Nephrology,the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Enshi 445000,China)
出处
《国际泌尿系统杂志》
2022年第3期466-470,共5页
International Journal of Urology and Nephrology
关键词
肾肿瘤
生长分化因子15
生物标记
肿瘤
Kidney Neoplasms
Growth Differentiation Factor 15
Biomarkers,Tumor
